ライフサイエンスコーパス: chromogranin A

1 al neuroendocrine distribution of endogenous chromogranin A.

2 onserved N- and C-terminal regions of bovine chromogranin A.

3 gation properties as compared with wild-type chromogranin A.

4 0% of cells, and absence of chymotrypsin and chromogranin A.

5 related peptide, neurotensin, serotonin, and chromogranin A.

6 f chymotrypsin, and rare immunoreactivity to chromogranin A.

7 immunostaining for tau-2, synaptophysin, and chromogranin A.

8 n fragments, and was liberated from purified chromogranin A.

9 o label with antibodies specific for APP and chromogranin A.

10 EVSSKDAAE, which is a degradation product of chromogranin A.

11 euroendocrine cell markers Synaptophysin and Chromogranin A.

12 g, urinary catecholamines/metanephrines, and chromogranin A.

13 ed 2 neuroendocrine tumor markers, ASCL1 and chromogranin A.

14 of cells expressing the pan-endocrine marker chromogranin A.

15 and neuroendocrine markers synaptophysin and chromogranin A.

16 PA PET/CT results had higher values of serum chromogranin A (100% vs. 20%, P = 0.0003), serotonin, or

17 Among 37 patients with elevated chromogranin A, 26 (70%) achieved normalization or more

18 Synthetic longer (chromogranin A(332-364)) and shorter (chromogranin A(344

19 trometry, a major catestatin form was bovine chromogranin A(332-364); identity of the peptide was con

20 alysis revealed two additional forms: bovine chromogranin A(333-364) and A(343-362).

21 strin (1031 pg/ml; reference value <108) and chromogranin A (337 U/L; reference value <36).

22 omaffin granules, with the major form, human chromogranin A(340-372), bounded by dibasic sites.

23 onger (chromogranin A(332-364)) and shorter (chromogranin A(344-364)) versions of catestatin each inh

24 tes highly O-glycosylated proteins including Chromogranin A, a key player in dense core granulogenesi

25 Serum chromogranin A, a marker for neuroendocrine tumors, is e

26 nase) blocked nicotinic or PMA activation of chromogranin A, although a dominant negative Ras mutant

27 s of the CT pulmonary angiographic findings, chromogranin A and 5-hydroxyindoleacetic acid levels wer

28 Tumor markers (chromogranin A and 5-hydroxyindoleacetic acid) before an

29 levels of oxytocin and peptides derived from chromogranin A and B dramatically decreased in the PC1 K

30 proopiomelanocortin, protachykinins A and B, chromogranin A and B, and secretogranin II.

31 ically abolished regulated secretion of both chromogranin A and beta-endorphin in response to the usu

32 GFI1 colocalizes with chromogranin A and calcitonin-gene-related peptide in em

33 nclude insulin and the two new autoantigens, chromogranin A and islet amyloid polypeptide, all protei

34 Thus, chromogranin A and its catestatin fragment may lie at th

35 eals that the interaction between fragmented chromogranin A and neuropilin-1 is required for tumor gr

36 a radioimmunoassays showed elevated gastrin, chromogranin A and normal levels of gastrin-releasing pe

37 Plasma chromogranin A and normetanephrine were the best tumor-m

38 Staining is negative for chromogranin A and positive for bombesin, serotonin, neu

39 alize with secretory granule markers such as chromogranin A and Rab27b, whereas Myo5c tubules are lab

40 r panendocrine immunohistochemistry markers (chromogranin A and/or synaptophysin); 35% of NETs demons

41 Chromogranins A and B (CGA and CGB) are high capacity, l

42 Chromogranins A and B (CGA and CGB), the major proteins

43 Chromogranins A and B and secretogranin II are a family

44 Chromogranins A and B are high capacity, low affinity ca

45 ch activation, and secretory markers Mucin2, Chromogranin A, and Growth factor-independent 1 (Gfi1) w

46 Different amidation events on chromogranin A, and on peptides processed from proopiome

47 rade [poorly differentiated], respectively), chromogranin A, and proliferation index (Ki-67).

48 Chromogranin A appears to be the most useful serum marke

49 found extensive processing of catestatin in chromogranin A, as judged by catestatin radioimmunoassay

50 in positively for alpha-tubulin, mucins, and chromogranin A, as well as for endoderm transcription fa

51 In summary, common variants in chromogranin A associate with the risk of hypertensive E

52 t express typical LDCV proteins, transfected chromogranins A, B, and brain-derived neurotrophic facto

53 efore probed the role of the MAPK pathway in chromogranin A biosynthesis after secretory stimulation

54 ntestinal enteroendocrine cells positive for chromogranin A, but they had normal numbers of Paneth's,

55 We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment

56 t, removing the C-terminal 90 amino acids of chromogranin A caused rerouting to the constitutive secr

57 ratin 20), acinar (chymotrypsin), and islet (chromogranin A) cell markers was performed to analyze th

58 ol as a well-known marker of stress loading, chromogranin A (CgA) and alpha-amylase (AA) are supposed

59 Results showed that proteolytic fragments of chromogranin A (CgA) and chromogranin B (CgB) represent

60 secretory vesicles of neuroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been

61 LDCV formation involves the granin proteins chromogranin A (CgA) and chromogranin B (CgB); CgA- and

62 nocarcinomas correlates with serum levels of chromogranin A (CgA) and drives treatment resistance.

63 Chromogranin A (CgA) and neuron-specific enolase (NSE) w

64 Immunohistochemical (IHC) measurement of chromogranin A (CgA) discriminates gastrointestinal (GI)

65 Previously, chromogranin A (CgA) has been shown to play a key role i

66 afficking of the regulated secretory protein chromogranin A (CgA) in PC12 cells.

67 Chromogranin A (CgA) is the major soluble protein in the

68 These conditions are reversed in Chromogranin A (CgA) knockout (CgA-KO) mice.

69 Chromogranin A (CgA) levels have previously been found t

70 Chromogranin A (CgA) may be critical for secretory granu

71 n active 21-residue peptide derived from the chromogranin A (CgA) precursor, and catestatin is secret

72 In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biom

73 iated with increased cleavage of full-length chromogranin A (CgA), a circulating vasoregulatory neuro

74 ing and organ colonization were inhibited by chromogranin A (CgA), a protein present in variable amou

75 ctors to 125 species and observed that fecal chromogranin A (CgA), a protein secreted by enteroendocr

76 found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroend

77 stores in which the Ca(2+) storage protein, chromogranin A (CGA), couples with InsP(3)-gated Ca(2+)

78 gnosis is established by elevation of plasma chromogranin A (CgA), serotonin, or urinary 5-hydroxyind

79 r Musashi-1 (Msi-1), neurogenin 3 (NEUROG3), chromogranin A (CgA), serotonin, peptide YY (PYY), oxynt

80 Chromogranin A (CgA), the major soluble protein in catec

81 Chromogranin A (CgA), which binds catecholamines for sto

82 cription of the major vesicular core protein chromogranin A (CgA).

83 secretion in endocrine cells is dependent on chromogranin A (CGA).

84 age product of the neuroendocrine prohormone chromogranin A (CgA).

85 n, increased tumor grade, and elevated serum chromogranin A (CgA).

86 cells, we show that SgIII is complexed with Chromogranin A (CgA).

87 e neuroendocrine (NE) markers calcitonin and chromogranin A (CgA).

88 the N- and C-terminal regions of circulating chromogranin A (CgA, CHGA), classically an antiangiogeni

89 and chemotherapy, presence of diabetes, and chromogranin-A (CgA) levels higher than 336 mug/L.

90 The 2.5HIP (C-peptide-chromogranin A [CgA] HIP), recognized by the diabetogeni

91 Chromogranin A (CHGA) and its derived peptides, which ar

92 n C-peptide fragment fused to a peptide from chromogranin A (ChgA) and that endogenous 2.5HIP-reactiv

93 es, we have identified the peptide WE14 from chromogranin A (ChgA) as the antigen for highly diabetog

94 , which is a fusion of insulin C-peptide and chromogranin A (ChgA) fragments, and compared it with th

95 Chromogranin A (ChgA) has been identified as the antigen

96 Recent studies suggest an important role of chromogranin A (CHGA) in the regulated secretory pathway

97 Chromogranin A (ChgA) is an autoantigen for CD4(+) T cel

98 The acidic glycoprotein chromogranin A (CHGA) is co-stored/co-secreted with cate

99 Chromogranin A (CHGA) is coreleased with catecholamines

100 The secretory pro-hormone chromogranin A (CHGA) is densely packed into storage gra

101 The secretory prohormone chromogranin A (CHGA) is overexpressed in essential hype

102 etermine whether the common variation at the chromogranin A (CHGA) locus increases susceptibility to

103 Whether chromogranin A (CHGA) polymorphisms predict end-organ co

104 Chromogranin A (CHGA) regulates catecholamine storage an

105 Chromogranin A (CHGA) regulates the storage and release

106 Chromogranin A (CHGA) triggers catecholamine secretory g

107 mimotope (BDC2.5(mim)) of islet autoantigen chromogranin A (ChgA) with or without calcitriol (1alpha

108 Chromogranin A (CHGA), a protein released from secretory

109 bal T1D serum proteomics analysis identified chromogranin A (CHGA), a T1D-autoantigen, as the top pro

110 mine release inhibitory peptide derived from chromogranin A (CHGA), and other CHGA- or chromogranin B

111 ied the beta cell secretory granule protein, chromogranin A (ChgA), as a new autoantigen in type 1 di

112 tide derived from the neuroendocrine protein chromogranin A (CHGA), is a functional AMP and is presen

113 Chromogranin A (Chga), which catalyzes formation and car

114 Catestatin (CST), a chromogranin A (CHGA)-derived peptide, is a potent inhib

115 Chromogranin A (CHGA/Chga), a proprotein, widely distrib

116 esicular monoamine transporter (VMAT1,2) and chromogranin A (ChrgA), are also expressed in taste buds

117 Chromogranin A, chromogranin B, and secretogranin II, me

118 ocortin (POMC), provasopressin, prooxytocin, chromogranin A, chromogranin B, and secretogranin II.

119 ells revealed reciprocal changes in secreted chromogranin A COOH-terminal fragments (increased approx

120 Chromogranin A, coreleased with catecholamines by exocyt

121 Point mutations of the chromogranin A CRE suggested that this element was neces

122 Here, we probed the role of the chromogranin A-derived peptide pancreastatin (PST: CHGA(

123 Pancreastatin (PST), a chromogranin A-derived peptide, is a potent physiologica

124 orms of gastrin in each, and pyloric mucosal chromogranin A-derived peptides were investigated in the

125 nces in the concentration of pyloric mucosal chromogranin A-derived peptides were recorded between in

126 Pancreastatin (PST), a chromogranin A-derived potent physiological dysglycemic

127 d secretion in both neuroendocrine cells and chromogranin A-expressing COS7 cells used as a simplifie

128 psies confirmed the presence of the virus in chromogranin A-expressing epithelial cells, as it does i

129 Both the MAPK pathway and chromogranin A expression may be activated by cytosolic

130 ues representing subsequent recurrences, the Chromogranin A expression was lost, and the Ki-67 index

131 Serum markers include chromogranin A for neuroendocrine tumors, pepsinogen I f

132 tely 71 and approximately 27 kD NH2-terminal chromogranin A fragments.

133 PACAP activated the endogenous chromogranin A gene by four- to fivefold.

134 IGF-I stimulated chromogranin A gene expression by Northern blot analysis

135 led with assay of histidine decarboxylase or chromogranin A gene expression is useful in the assessme

136 ed whether PACAP regulates expression of the chromogranin A gene in PC12 rat chromaffin cells, so as

137 in, performance status, tumor burden, plasma chromogranin A (>/=600 mug/L), neuron-specific enolase (

138 Tissue morphology, abundance of chromogranin A, gut hormones, alpha-defensin, mucin 2, N

139 Chromogranin A immunoblots revealed chromogranin A proce

140 tion was used to analyze the distribution of chromogranin A immunoreactive cells in serial sections o

141 injection, total insulin content and insulin:chromogranin A immunoreactivity were reduced by approxim

142 Therefore, the global deficiency of chromogranin A impairs recognition of the major diabetog

143 hemistry demonstrated a relative decrease of chromogranin A in processes (where regulated secretory v

144 retory granules, and stimulated secretion of chromogranin A increased 50%.

145 imulation of secretion in catecholamines and chromogranin A, indicating that secretion of solAPPcyt w

146 cells did not express defensin-5, Muc-2, or chromogranin A, indicating that they were not lineage co

147 Hybrid-insulin C-chromogranin A (InsC-ChgA)-specific CD4(+) T cells skewe

148 Although various biomarkers including CHGA (Chromogranin A), INSM1 (Insulinoma-associated protein 1)

149 Specific endopeptidases cleave chromogranin A into biologically active peptide fragment

150 These results demonstrate that chromogranin A is a substrate for the endogenous endopro

151 The catestatin fragment of chromogranin A is an endogenous inhibitor of nicotinic c

152 The catestatin fragment of chromogranin A is an inhibitor of catecholamine release,

153 This region of chromogranin A is extensively processed within chromaffi

154 Chromogranin A is released together with epinephrine and

155 Since chromogranin A is secreted along with catecholamines, we

156 Chromogranin A is the major soluble core component in se

157 Chromogranin A knock-out (Chga-KO) mice display increase

158 Chromogranin A knockout (Chga-KO) mice exhibit enhanced

159 are and characterise human EECs we generated chromogranin-A labelled organoids from duodenal and ilea

160 ng a greater than 50% reduction in the nadir chromogranin A level within the 1st year after treatment

161 estimated absorbed BM dose, elevated plasma chromogranin A level, baseline blood counts, and renal f

162 Her 5-hydroxyindoleacetic acid and chromogranin A levels were not elevated.

163 Chromogranin A levels were significantly higher in both

164 rmal, as were 5-hydroxyindoleacetic acid and chromogranin A levels.

165 on of PCl suggests that the action of PC1 on chromogranin A may be specific within the chromogranin/s

166 and calcitonin and suggest that the role of chromogranin A may be to stabilize an otherwise unstable

167 This small domain within chromogranin A may contribute to a novel, autocrine, hom

168 owledge of cleavage sites of catestatin from chromogranin A may provide a useful starting point in an

169 function, e.g., histidine decarboxylase and chromogranin A messenger RNA abundance, in carcinoid tum

170 NH2-terminal fragment as well as the parent chromogranin A molecule accumulated, while an approximat

171 eprazole, VMAT2, histidine decarboxylase and chromogranin A mRNA abundance in gastric corpus, and pla

172 Chromogranin A mRNA responded to MAPK pathway manipulati

173 Chromogranin A mRNA showed a time-dependent 3.87-fold re

174 ng for mucosal 5-HT synthesis; P < 0.01] and chromogranin A (neuroendocrine secretion; P < 0.01), wit

175 The baseline levels of chromogranin A, neuron-specific enolase, and multiple so

176 We also measured fasting serum chromogranin A, neuron-specific enolase, gastrin, glucag

177 Elevated baseline chromogranin A, neuron-specific enolase, placental growt

178 n L-DsRed fusion protein with enkephalin and chromogranin A neuropeptides that are present in secreto

179 isense PC1 induction, an approximately 66-kD chromogranin A NH2-terminal fragment as well as the pare

180 hetic peptides spanning approximately 80% of chromogranin A, one (bovine chromogranin A344-364 [RSMRL

181 and neuroendocrine markers synaptophysin and chromogranin A (P < 0.0000001).

182 Fluorescent chromogranin-A positive EECs were purified and analysed

183 We report increased numbers of chromogranin A-positive (+), including orexigenic ghreli

184 as predominantly localized to epithelial and chromogranin A-positive endocrine cells.

185 et cell function while negatively regulating chromogranin A-positive enteroendocrine cell number.

186 inantly in intestinal epithelial cells, with chromogranin A-positive enteroendocrine cells (EECs) ide

187 otyping, including catecholamine production, chromogranin A precursor, and its catestatin product.

188 Chromogranin A immunoblots revealed chromogranin A processing, from both the NH2 and COOH te

189 A series of chromogranin A promoter 5' deletion mutant/luciferase re

190 markedly diminished trans-activation of the chromogranin A promoter by PACAP.

191 r was in linkage disequilibrium with 1 major Chromogranin A promoter haplotype, although promoter hap

192 cis, activation by the cascade maps onto the chromogranin A promoter proximal CRE, which is both nece

193 , and calcium-dependent signals map onto the chromogranin A promoter proximal CRE.

194 oximal CRE box is entirely necessary for the chromogranin A promoter response to PACAP.

195 kinase blocked the response of a transfected chromogranin A promoter to nicotine or protein kinase C

196 antagonist KCREB blocked the response of the chromogranin A promoter to nicotine, cAMP, or MAPK pathw

197 protein kinase C mapped principally onto the chromogranin A promoter's cAMP response element (TGACGTA

198 ltimately relays the secretory signal to the chromogranin A promoter's CRE box in cis.

199 tion in a fashion similar to the transfected chromogranin A promoter, in both direction and magnitude

200 n enhanced basal as well as IGF-I-stimulated chromogranin A promoter.

201 fection of pathway components stimulated the chromogranin A promoter.

202 we employed a novel mouse strain harboring a chromogranin A promoter/firefly luciferase reporter tran

203 e obtained with a transfected 1,200-bp mouse chromogranin A promoter/luciferase reporter construct.

204 Transfected chromogranin A promoter/luciferase reporter constructs w

205 the fluorescent protein Venus driven by the chromogranin-A promoter.

206 Generation of NOD mice lacking the chromogranin A protein (NOD.ChgA(-/-)) completely nullif

207 hypothesis, recombinant insulin, GAD65, and chromogranin A proteins were encapsulated within poly(d,

208 edistribution of desmoplakin, keratin 5, and chromogranin A proteins.

209 istochemistry for cytokeratins 7 and 20, and Chromogranin A-proteins which have a well described expr

210 his peptide blocked the inhibitory effect of chromogranin A proteolytic fragments on nicotinic-stimul

211 differentiation of thymocytes expressing the chromogranin A-reactive BDC-2.5 and BDC-10.1 TCRs or the

212 ay not be solely explained by the absence of chromogranin A reactivity.

213 atecholamine release, and was shared by this chromogranin A region from several species.

214 ced secretion, transcriptional activation of chromogranin A remained unaltered.

215 gen receptor, prostate specific antigen, and chromogranin A, respectively.

216 as associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic r

217 sphatase and the regulated secretory protein chromogranin A resulted in an increased chromogranin sto

218 and-Factor[rs12829220] in the control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vit

219 Plasma cortisol and chromogranin A showed a significant association that did

220 The frequencies of islet Ag-reactive chromogranin A-specific CD4(+) T cells and islet specifi

221 marker MTA1, the apoptotic marker NALP, and chromogranin A) that define gut neuroendocrine cell beha

222 biosynthesis of the major secreted protein (chromogranin A), that the activation is transcriptional,

223 secretion also activates the biosynthesis of chromogranin A, the major protein released with catechol

224 lls, we studied the biosynthetic response of chromogranin A, the major soluble protein co-stored and

225 Such coupling triggers the biosynthesis of chromogranin A, the precursor of catestatin.

226 ynthesis of just released catecholamines and chromogranin A, the precursor of the catecholamine relea

227 ization domain did not affect the sorting of chromogranin A to the regulated secretory pathway.

228 Thus, PACAP-evoked chromogranin A transcription and catecholamine secretion

229 -binding protein CREB, blunted activation of chromogranin A transcription by nicotine, phorbol ester,

230 We conclude that activation of chromogranin A transcription by secretory stimulation in

231 receptor antagonist PACAP6-38 impaired both chromogranin A transcription or catecholamine secretion

232 Therefore, we propose that PACAP signals to chromogranin A transcription through the CRE in cis, and

233 bited both forskolin and PACAP activation of chromogranin A transcription, revealing that PACAP-induc

234 timuli influence exocytotic secretion versus chromogranin A transcription.

235 gene-3; stem (BMI1, nestin); and chromaffin (chromogranin A, tyrosine hydroxylase) markers similar to

236 Chromogranin A was identified as a promising marker for

237 a new phosphorylation site (S191) in bovine chromogranin A was identified.

238 eporter and the neuroendocrine-specific gene chromogranin A was induced 2-3.3-fold by insulin-like gr

239 Plasma levels of cortisol and chromogranin-A were determined.

240 easing peptide, neuron-specific enolase, and chromogranin-A) were analyzed in 50 patients commencing